COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assesse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the neurological sciences Jg. 434; S. 120155
Hauptverfasser: Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier B.V 15.03.2022
Schlagworte:
Acute relapse
Adult
Adverse events
Antibodies, Viral
BNT162 Vaccine
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
Humans
Immune response
Multiple sclerosis
Multiple Sclerosis - drug therapy
Neurology
SARS-CoV-2
Third booster dose
Vaccination
Vaccination - adverse effects
COVID-19
Third booster dose
Multiple sclerosis
Immune response
Adverse events
Vaccination
Acute relapse
ISSN:0022-510X, 1878-5883, 1878-5883
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assessed. Characterize safety and humoral immune response following the third dose of COVID-19 vaccination in a large cohort of MS patients. We assessed the safety of the third dose of the BNT162b2-COVID-19 mRNA vaccination in adult MS patients and evaluated SARS-CoV-2 IgG response. Two hundred and eleven adult MS patients received a third dose of BNT162b2 COVID-19 vaccination. Median follow up time was 66 days from vaccine administration (IQR 54–84). The frequency of any adverse event was 54.5%, with the most common reported adverse events being fatigue, local pain at the injection site, fever and muscle or joint pain. Transient increase in MS symptoms was reported in 3.8% of patients, none of them requiring treatment. The rate of acute relapses treated with IV steroids was 3.3%. In a sub-group of 55 patients, 20 untreated and 35 treated with vaccination-safe disease-modifying treatments, SARS-CoV-2 IgG levels increased 21-fold (median ± SD 21.6 ± 53.05). The third dose of COVID-19-BNT162b2 vaccine proved safe for MS patients, with no increased risk of relapse activity. Untreated patients and patients treated with vaccination-safe disease-modifying treatments show significant increase in SARS-CoV-2 IgG levels following the third dose of vaccination. •The third dose resulted in adverse events profile similar to that following the first and second doses.•No increased risk for relapse activity following the third vaccine dose was observed within a follow-up of 2 months.•Paired kinetics of anti-spike IgG titers revealed a 21-fold increase in up to 3 months following the third dose.•This finding held true both in untreated and in vaccination–safe DMTs treated MS patients.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-510X
1878-5883
1878-5883
DOI:10.1016/j.jns.2022.120155